The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure
2 other identifiers
interventional
8
1 country
1
Brief Summary
The main objective of this study is to investigate the effect of Prometheus liver support dialysis on intracranial pressure, cerebral metabolism and circulation in patients with acute liver failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
April 3, 2008
CompletedFirst Posted
Study publicly available on registry
April 9, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedJuly 27, 2011
July 1, 2010
3.8 years
April 3, 2008
July 26, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
treatment effect on cerebral oxidative metabolism (lactate/pyruvate-ratio)
24 hours
Secondary Outcomes (1)
treatment effect on intracranial pressure
24 hours
Study Arms (2)
1
ACTIVE COMPARATORTreatment with 6-8 hours of Prometheus (R) liver support dialysis
2
ACTIVE COMPARATORTreatment with 6-8 hours of CVVHDF
Interventions
6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
Eligibility Criteria
You may qualify if:
- acute liver failure
- and grade II-IV encephalopathy
- and persistent raised arterial ammonia-concentration above 150 micromol/L
- and informed consent from closest relative and general practitioner
You may not qualify if:
- withdrawal of informed consent
- severe untreated infection
- active bleeding within 48 hours
- suspicion of malignant liver disease
- severe heart insufficiency or middle artery pressure below 60 mmHg in spite of vasoactive therapy
- pregnant or lactating women
- disseminated intravascular coagulation
- clinical suspicion of cerebral damage
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The liverfailure unit, Department of hepatology, Rigshospitalet
Copenhagen, 2100, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter N Bjerring, MD
Department of Hepatology, Rigshospitalet
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 3, 2008
First Posted
April 9, 2008
Study Start
March 1, 2007
Primary Completion
December 1, 2010
Study Completion
June 1, 2011
Last Updated
July 27, 2011
Record last verified: 2010-07